Valiant Co.,Ltd. Reports Higher Year-on-Year Revenue in Life Sciences and Pharmaceutical Business for Q3 2025

Deep News11-21

Valiant Co.,Ltd. (002643) announced that its life sciences and pharmaceutical business segment achieved higher overall revenue in the third quarter of 2025 compared to the same period last year. The company did not disclose specific financial figures in this preliminary report.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment